Little Known Facts About ABBV-744 as a potential therapeutic option for aggressive cancers.
In Phase C, individuals will acquire ABBV-744 and oral navitoclax. In Segment D, members will acquire ABBV-744 and ruxolitinib. Individuals will get treatment until eventually ailment progression or the individuals are not able to tolerate the study drugs.and after that boost H3K27Ac at this region. Chromatin hyperacetylation could enhance the acce